Now that it is in the Bombay Stock Exchange Sensitive Index, Sun is likely to gain back its valuations and get credit for due diversifications, with Emerging Market JVs with Pfizer from SPARC and Taro's full year results as well. 

It also got FDA approval for Imitrex this week. Imitrex is an injectible (statdose??) from GSK. Annual sales of the single dose syringe come to $190 million so Sun can probably look at around $28 mln from the produc without extensive marketing investments

Posted via email from The investment blog on Post